Request for Medicare Payment Advisory Commission (MedPAC) Nominations, 2426 [2020-00521]
Download as PDF
<![CDATA[
2426
Federal Register / Vol. 85, No. 10 / Wednesday, January 15, 2020 / Notices
Request for Medicare Payment
Advisory Commission (MedPAC)
Nominations
U.S. Government
Accountability Office (GAO).
ACTION: Request for letters of
nomination and resumes.
AGENCY:
The Balanced Budget Act of
1997 established the Medicare Payment
Advisory Commission (MedPAC) and
gave the Comptroller General
responsibility for appointing its
members. GAO is now accepting
nominations for MedPAC appointments
that will be effective May 2020.
Nominations should be sent to the email
or mailing address listed below.
Acknowledgement of submissions will
be provided within a week of
submission.
SUMMARY:
Letters of nomination and
resumes should be submitted no later
than February 14, 2020, to ensure
adequate opportunity for review and
consideration of nominees prior to
appointment.
DATES:
Submit letters of
nomination and resumes by either of the
following methods: Email:
MedPACappointments@gao.gov or Mail:
U.S. GAO, Attn: MedPAC
Appointments, 441 G Street NW,
Washington, DC 20548.
FOR FURTHER INFORMATION CONTACT:
Gregory Giusto at (202) 512–8268 or
giustog@gao.gov if you do not receive an
acknowledgement or need additional
information. For general information,
contact GAO’s Office of Public Affairs,
(202) 512–4800.
ADDRESSES:
Authority: 42 U.S.C. 1395b–6.
Gene L. Dodaro,
Comptroller General of the United States.
[FR Doc. 2020–00521 Filed 1–14–20; 8:45 am]
BILLING CODE 1610–02–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
jbell on DSKJLSW7X2PROD with NOTICES
Agency for Healthcare Research and
Quality
Supplemental Evidence and Data
Request on Treatments for Acute
Episodic Migraine
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for supplemental
evidence and data submissions.
AGENCY:
VerDate Sep<11>2014
17:18 Jan 14, 2020
Jkt 250001
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
Treatments for Acute Episodic Migraine,
which is currently being conducted by
the AHRQ’s Evidence-based Practice
Centers (EPC) Program. Access to
published and unpublished pertinent
scientific information will improve the
quality of this review.
DATES: Submission Deadline on or
before 30 days after date of publication
in Federal Register.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
Healthcare Research and Quality,
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane,
Mail Stop 06E77D, Rockville, MD
20857.
FOR FURTHER INFORMATION CONTACT:
Jenae Benns, Telephone: 301–427–1496
or Email: epc@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for Treatments for Acute
Episodic Migraine. AHRQ is conducting
this systematic review pursuant to
Section 902(a) of the Public Health
Service Act, 42 U.S.C. 299a(a).
The EPC Program is dedicated to
identifying as many studies as possible
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on Treatments for Acute
Episodic Migraine, including those that
describe adverse events. The entire
research protocol is available online at:
https://effectivehealthcare.ahrq.gov/
products/migraine-treatments/protocol.
This is to notify the public that the
EPC Program would find the following
information on Treatments for Acute
Episodic Migraine helpful:
D A list of completed studies that
your organization has sponsored for this
indication. In the list, please indicate
whether results are available on
SUMMARY:
GOVERNMENT ACCOUNTABILITY
OFFICE
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements: Study number, study period,
design, methodology, indication and
diagnosis, proper use instructions,
inclusion and exclusion criteria,
primary and secondary outcomes,
baseline characteristics, number of
patients screened/eligible/enrolled/lost
to follow-up/withdrawn/analyzed,
effectiveness/efficacy, and safety results.
D A list of ongoing studies that your
organization has sponsored for this
indication. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including a study number, the
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, and primary and secondary
outcomes.
D Description of whether the above
studies constitute ALL Phase II and
above clinical trials sponsored by your
organization for this indication and an
index outlining the relevant information
in each submitted file.
Your contribution is very beneficial to
the Program. Materials submitted must
be publicly available or able to be made
public. Materials that are considered
confidential; marketing materials; study
types not included in the review; or
information on indications not included
in the review cannot be used by the EPC
Program. This is a voluntary request for
information, and all costs for complying
with this request must be borne by the
submitter.
The draft of this review will be posted
on AHRQ’s EPC Program website and
available for public comment for a
period of 4 weeks. If you would like to
be notified when the draft is posted,
please sign up for the email list at:
https://
www.effectivehealthcare.ahrq.gov/
email-updates.
The systematic review will answer the
following questions. This information is
provided as background. AHRQ is not
requesting that the public provide
answers to these questions.
Key Questions (KQ)
For patients with acute episodic
migraine.
KQ 1. Opioid Therapy
KQ1a. What is the comparative
effectiveness of opioid therapy versus:
(1) Nonopioid pharmacologic therapy
(e.g., acetaminophen, nonsteroidal antiinflammatory drugs [NSAIDs], triptans,
ergots alkaloids, combination
E:\FR\FM\15JAN1.SGM
15JAN1
]]>Agencies
[Federal Register Volume 85, Number 10 (Wednesday, January 15, 2020)]
[Notices]
[Page 2426]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-00521]
[[Page 2426]]
=======================================================================
-----------------------------------------------------------------------
GOVERNMENT ACCOUNTABILITY OFFICE
Request for Medicare Payment Advisory Commission (MedPAC)
Nominations
AGENCY: U.S. Government Accountability Office (GAO).
ACTION: Request for letters of nomination and resumes.
-----------------------------------------------------------------------
SUMMARY: The Balanced Budget Act of 1997 established the Medicare
Payment Advisory Commission (MedPAC) and gave the Comptroller General
responsibility for appointing its members. GAO is now accepting
nominations for MedPAC appointments that will be effective May 2020.
Nominations should be sent to the email or mailing address listed
below. Acknowledgement of submissions will be provided within a week of
submission.
DATES: Letters of nomination and resumes should be submitted no later
than February 14, 2020, to ensure adequate opportunity for review and
consideration of nominees prior to appointment.
ADDRESSES: Submit letters of nomination and resumes by either of the
following methods: Email: [email protected] or Mail: U.S. GAO,
Attn: MedPAC Appointments, 441 G Street NW, Washington, DC 20548.
FOR FURTHER INFORMATION CONTACT: Gregory Giusto at (202) 512-8268 or
[email protected] if you do not receive an acknowledgement or need
additional information. For general information, contact GAO's Office
of Public Affairs, (202) 512-4800.
Authority: 42 U.S.C. 1395b-6.
Gene L. Dodaro,
Comptroller General of the United States.
[FR Doc. 2020-00521 Filed 1-14-20; 8:45 am]
BILLING CODE 1610-02-P
